English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.42 |
| Open | 1.41 |
| 1-Year Change | -56.35% |
| Day's Range | 1.41 - 1.48 |
DarioHealth Corp.(DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. DarioHealth products include Dario blood glucose monitoring, Dario Blood Pressure Monitoring System, and Dario Smart Scale. The Dario blood glucose monitoring device is a system that measure sugar levels. The Dario Smart Scale is a blood pressure monitoring system used to measure blood pressure and stored in a digital logbook in the Dario App. It offers modular platform integrating digital therapeutics, coaching, devices, and care providers. Its suite of offerings includes Dario Tools, DarioEngage, and Dario Loop.
BRIEF: For the fiscal year ended 31 December 2021, DarioHealth Corp revenues increased from $7.6M to $20.5M. Net loss applicable to common stockholders increased from $33.1M to $78.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Marketing and Pre-Production Cost increase from $12.5M to $33.7M (expense).
Common Stock $0.0001 Par, Shares auth. 45M and o/s 19,240,234 issd. Insiders own approx. 14.03% (after the IPO). If no information is provided, use TBA. 10/14 1-for-5 reverse stock split. 03/2016, 1-For-18 Reverse Stock Split.
